Research ArticleArticle
Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study
John S. Sundy, H. Ralph Schumacher, Alan Kivitz, Steven P. Weinstein, Richard Wu, Shirletta King-Davis and Robert R. Evans
The Journal of Rheumatology July 2014, jrheum.131226; DOI: https://doi.org/10.3899/jrheum.131226
John S. Sundy
From the Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Rheumatology, VA Medical Center and University of Pennsylvania, Philadelphia; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, Pennsylvania; Department of Clinical Sciences Immunology and Inflammation, Department of Biostatistics, and the Department of Clinical Operations, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Funding provided by Regeneron Pharmaceuticals, Tarrytown, NY. Editorial support provided by E. Jay Bienen and funded by Regeneron Pharmaceuticals Inc. J.S. Sundy, MD, PhD, Department of Medicine, Duke University Medical Center; H.R. Schumacher, MD, Department of Rheumatology, VA Medical Center and University of Pennsylvania; A. Kivitz, MD, Department of Rheumatology, Altoona Center for Clinical Research; S.P. Weinstein, MD, PhD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc.; R. Wu, PhD, Department of Biostatistics, Regeneron Pharmaceuticals Inc.; S. King-Davis, RN, MS, Department of Clinical Operations, Regeneron Pharmaceuticals Inc.; R.R. Evans, PharmD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc. Address correspondence to Dr. J.S. Sundy, Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: john.sundy@duke.edu. Accepted for publication April 10, 2014.
H. Ralph Schumacher
From the Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Rheumatology, VA Medical Center and University of Pennsylvania, Philadelphia; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, Pennsylvania; Department of Clinical Sciences Immunology and Inflammation, Department of Biostatistics, and the Department of Clinical Operations, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Funding provided by Regeneron Pharmaceuticals, Tarrytown, NY. Editorial support provided by E. Jay Bienen and funded by Regeneron Pharmaceuticals Inc. J.S. Sundy, MD, PhD, Department of Medicine, Duke University Medical Center; H.R. Schumacher, MD, Department of Rheumatology, VA Medical Center and University of Pennsylvania; A. Kivitz, MD, Department of Rheumatology, Altoona Center for Clinical Research; S.P. Weinstein, MD, PhD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc.; R. Wu, PhD, Department of Biostatistics, Regeneron Pharmaceuticals Inc.; S. King-Davis, RN, MS, Department of Clinical Operations, Regeneron Pharmaceuticals Inc.; R.R. Evans, PharmD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc. Address correspondence to Dr. J.S. Sundy, Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: john.sundy@duke.edu. Accepted for publication April 10, 2014.
Alan Kivitz
From the Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Rheumatology, VA Medical Center and University of Pennsylvania, Philadelphia; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, Pennsylvania; Department of Clinical Sciences Immunology and Inflammation, Department of Biostatistics, and the Department of Clinical Operations, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Funding provided by Regeneron Pharmaceuticals, Tarrytown, NY. Editorial support provided by E. Jay Bienen and funded by Regeneron Pharmaceuticals Inc. J.S. Sundy, MD, PhD, Department of Medicine, Duke University Medical Center; H.R. Schumacher, MD, Department of Rheumatology, VA Medical Center and University of Pennsylvania; A. Kivitz, MD, Department of Rheumatology, Altoona Center for Clinical Research; S.P. Weinstein, MD, PhD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc.; R. Wu, PhD, Department of Biostatistics, Regeneron Pharmaceuticals Inc.; S. King-Davis, RN, MS, Department of Clinical Operations, Regeneron Pharmaceuticals Inc.; R.R. Evans, PharmD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc. Address correspondence to Dr. J.S. Sundy, Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: john.sundy@duke.edu. Accepted for publication April 10, 2014.
Steven P. Weinstein
From the Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Rheumatology, VA Medical Center and University of Pennsylvania, Philadelphia; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, Pennsylvania; Department of Clinical Sciences Immunology and Inflammation, Department of Biostatistics, and the Department of Clinical Operations, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Funding provided by Regeneron Pharmaceuticals, Tarrytown, NY. Editorial support provided by E. Jay Bienen and funded by Regeneron Pharmaceuticals Inc. J.S. Sundy, MD, PhD, Department of Medicine, Duke University Medical Center; H.R. Schumacher, MD, Department of Rheumatology, VA Medical Center and University of Pennsylvania; A. Kivitz, MD, Department of Rheumatology, Altoona Center for Clinical Research; S.P. Weinstein, MD, PhD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc.; R. Wu, PhD, Department of Biostatistics, Regeneron Pharmaceuticals Inc.; S. King-Davis, RN, MS, Department of Clinical Operations, Regeneron Pharmaceuticals Inc.; R.R. Evans, PharmD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc. Address correspondence to Dr. J.S. Sundy, Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: john.sundy@duke.edu. Accepted for publication April 10, 2014.
Richard Wu
From the Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Rheumatology, VA Medical Center and University of Pennsylvania, Philadelphia; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, Pennsylvania; Department of Clinical Sciences Immunology and Inflammation, Department of Biostatistics, and the Department of Clinical Operations, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Funding provided by Regeneron Pharmaceuticals, Tarrytown, NY. Editorial support provided by E. Jay Bienen and funded by Regeneron Pharmaceuticals Inc. J.S. Sundy, MD, PhD, Department of Medicine, Duke University Medical Center; H.R. Schumacher, MD, Department of Rheumatology, VA Medical Center and University of Pennsylvania; A. Kivitz, MD, Department of Rheumatology, Altoona Center for Clinical Research; S.P. Weinstein, MD, PhD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc.; R. Wu, PhD, Department of Biostatistics, Regeneron Pharmaceuticals Inc.; S. King-Davis, RN, MS, Department of Clinical Operations, Regeneron Pharmaceuticals Inc.; R.R. Evans, PharmD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc. Address correspondence to Dr. J.S. Sundy, Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: john.sundy@duke.edu. Accepted for publication April 10, 2014.
Shirletta King-Davis
From the Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Rheumatology, VA Medical Center and University of Pennsylvania, Philadelphia; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, Pennsylvania; Department of Clinical Sciences Immunology and Inflammation, Department of Biostatistics, and the Department of Clinical Operations, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Funding provided by Regeneron Pharmaceuticals, Tarrytown, NY. Editorial support provided by E. Jay Bienen and funded by Regeneron Pharmaceuticals Inc. J.S. Sundy, MD, PhD, Department of Medicine, Duke University Medical Center; H.R. Schumacher, MD, Department of Rheumatology, VA Medical Center and University of Pennsylvania; A. Kivitz, MD, Department of Rheumatology, Altoona Center for Clinical Research; S.P. Weinstein, MD, PhD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc.; R. Wu, PhD, Department of Biostatistics, Regeneron Pharmaceuticals Inc.; S. King-Davis, RN, MS, Department of Clinical Operations, Regeneron Pharmaceuticals Inc.; R.R. Evans, PharmD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc. Address correspondence to Dr. J.S. Sundy, Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: john.sundy@duke.edu. Accepted for publication April 10, 2014.
Robert R. Evans
From the Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Rheumatology, VA Medical Center and University of Pennsylvania, Philadelphia; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, Pennsylvania; Department of Clinical Sciences Immunology and Inflammation, Department of Biostatistics, and the Department of Clinical Operations, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Funding provided by Regeneron Pharmaceuticals, Tarrytown, NY. Editorial support provided by E. Jay Bienen and funded by Regeneron Pharmaceuticals Inc. J.S. Sundy, MD, PhD, Department of Medicine, Duke University Medical Center; H.R. Schumacher, MD, Department of Rheumatology, VA Medical Center and University of Pennsylvania; A. Kivitz, MD, Department of Rheumatology, Altoona Center for Clinical Research; S.P. Weinstein, MD, PhD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc.; R. Wu, PhD, Department of Biostatistics, Regeneron Pharmaceuticals Inc.; S. King-Davis, RN, MS, Department of Clinical Operations, Regeneron Pharmaceuticals Inc.; R.R. Evans, PharmD, Department of Clinical Sciences Immunology and Inflammation, Regeneron Pharmaceuticals Inc. Address correspondence to Dr. J.S. Sundy, Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: john.sundy@duke.edu. Accepted for publication April 10, 2014.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study
John S. Sundy, H. Ralph Schumacher, Alan Kivitz, Steven P. Weinstein, Richard Wu, Shirletta King-Davis, Robert R. Evans
The Journal of Rheumatology Jul 2014, jrheum.131226; DOI: 10.3899/jrheum.131226
Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study
John S. Sundy, H. Ralph Schumacher, Alan Kivitz, Steven P. Weinstein, Richard Wu, Shirletta King-Davis, Robert R. Evans
The Journal of Rheumatology Jul 2014, jrheum.131226; DOI: 10.3899/jrheum.131226